

INTERNATIONAL TRADE COMMISSION

[USITC SE-05-045]

Sunshine Act Meeting**AGENCY HOLDING THE MEETING:** United States International Trade Commission.**TIME AND DATE:** December 21, 2005 at 11 a.m.**PLACE:** Room 101, 500 E Street, SW., Washington, DC 20436, Telephone: (202) 205-2000.**STATUS:** Open to the public.**MATTERS TO BE CONSIDERED:**

1. Agenda for future meetings: None.
2. Minutes.
3. Ratification List.
4. Inv. No. 731-TA-377 (Second Review) (Internal Combustion Industrial Forklift Trucks from Japan)—briefing and vote. (The Commission is currently scheduled to transmit its determination and Commissioners' opinions to the Secretary of Commerce on or before January 5, 2006.)
5. Outstanding action jackets: none.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.

Issued: December 6, 2005.

By order of the Commission.

Marilyn R. Abbott,

Secretary to the Commission.

[FR Doc. 05-23940 Filed 12-7-05; 3:32 pm]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE**Drug Enforcement Administration**

[DEA # 270E]

Controlled Substances: Established Initial Aggregate Production Quotas for 2006**AGENCY:** Drug Enforcement Administration (DEA), Justice.**ACTION:** Notice of aggregate production quotas for 2006.

SUMMARY: This notice establishes initial 2006 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

DATES: Effective Date: December 9, 2005.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,

Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has re-delegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104.

The 2006 aggregate production quotas represent those quantities of controlled substances that may be produced in the United States in 2006 to provide adequate supplies of each substance for: the estimated medical, scientific, research and industrial needs of the United States; lawful export requirements; and the establishment and maintenance of reserve stocks (21 U.S.C. 826(a) and 21 CFR 1303.11). These quotas do not include imports of controlled substances for use in industrial processes.

On October 21, 2005, a notice of the proposed initial 2006 aggregate production quotas for certain controlled substances in Schedules I and II was published in the **Federal Register** (FR 61310). All interested persons were invited to comment on or object to these proposed aggregate production quotas on or before November 14, 2005.

Eight responses were received resulting in comments on a total of 24 Schedule I and II controlled substances within the published comment period. The responses commented that the proposed aggregate production quotas for 4-methoxyamphetamine, amphetamine, codeine (for conversion), codeine (for sale), difenoxin, dihydrocodeine, dihydromorphine, diphenoxylate, fentanyl, gamma-hydroxybutyric acid (GHB), hydrocodone, hydromorphone, meperidine, methamphetamine, methylphenidate, morphine, morphine (for conversion), noroxymorphone (for conversion), oxycodone, oxymorphone, pentobarbital, remifentanyl, sufentanyl and tetrahydrocannabinols were insufficient to provide for the estimated medical, scientific, research and industrial needs of the United States, for export requirements and for the establishment and maintenance of reserve stocks.

DEA has taken into consideration the above comments along with the relevant

2005 manufacturing quotas, current 2005 sales and inventories, 2006 export requirements, additional applications received, and research and product development requirements. Based on this information, the DEA has adjusted the initial aggregate production quotas for 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-N-ethylamphetamine (MDEA), 3,4-methylenedioxy-methamphetamine (MDMA), 4-methoxyamphetamine, 4-methyl-2,5-dimethoxyamphetamine (DOM), bufotenine, cathinone, codeine-N-oxide, heroin, methaqualone, morphine-N-oxide, normorphine, psilocybin, alfentanil, amobarbital, amphetamine, cocaine, dihydrocodeine, ecgonine, hydrocodone (for sale), levorphanol, levorphanol (LAAM), levomethorphan, methadone (for sale), methadone intermediate, methamphetamine, methamphetamine (for conversion), noroxymorphone (for conversion), pentobarbital, phencyclidine, remifentanyl and sufentanyl to meet the legitimate needs of the United States.

Regarding codeine (for conversion), codeine (for sale), difenoxin, dihydromorphine, diphenoxylate, fentanyl, gamma-hydroxybutyric acid (GHB), hydromorphone, meperidine, methylphenidate, morphine, morphine (for conversion), oxycodone, oxymorphone, and tetrahydrocannabinols, the DEA has determined that the proposed initial 2006 aggregate production quotas are sufficient to meet the current 2006 estimated medical, scientific, research and industrial needs of the United States.

Pursuant to 21 CFR part 1303, the Deputy Administrator of the DEA will, in 2006, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 2005 year-end inventory and actual 2005 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance.

Therefore, under the authority vested in the Attorney General by Section 306 of the CSA (21 U.S.C. 826), and delegated to the Administrator of the DEA by 28 CFR 0.100, and re-delegated to the Deputy Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby orders that the 2006 initial aggregate production quotas for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows: